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Abstract: We evaluated whether physiological and pre-eclamptic (PE) placentae, characterized by
exacerbated inflammation, presented alterations in pro-inflammatory High Mobility Group Box 1
(HMGB1) and its Receptor of Advanced Glycation End products (RAGE) expression. Moreover, we
investigated, in physiological placental tissue, the ability of Low Molecular Weight Heparin (LMWH)
to modify HMGB1 structural conformation thus inhibiting RAGE binding and HMGB1/RAGE axis
inflammatory activity. HMGB1, RAGE, IL-6 and TNFα (HMGB1/RAGE targets) mRNA expression
were assessed by Real Time PCR. HMGB1, RAGE protein levels were assessed by western blot assay.
Physiological term placental explants were treated by 0.5 U LMWH for 24 or 48 h. HMGB1 and
RAGE expression and association were evaluated in LMWH explants by RAGE immunoprecipitation
followed by HMGB1 immunoblot. HMGB1 spatial localization was evaluated by immuofluorescent
staining (IF). HMGB1 expression was increased in PE relative to physiological placentae while RAGE
was unvaried. 24 h LMWH treatment significantly up-regulated HMGB1 expression but inhibited
HMGB1/RAGE complex formation in physiological explants. RAGE expression decreased in treated
relative to untreated explants at 48 h. IF showed HMGB1 localization in both cytoplasm and nucleus
of mesenchymal and endothelial cells but not in the trophoblast. IL-6 and TNFα gene expression were
significantly increased at 24 h relative to controls, while they were significantly down-regulated in
48 h vs. 24 h LMWH explants. Our data depicted a new molecular mechanism through which LMWH
exerts its anti-inflammatory effect on PE placentae, underlying the importance of HMGB1/RAGE
axis in PE inflammatory response.
Keywords: heparin; HMGB1; placenta; pre-eclampsia; receptor for advanced glycation end
products (RAGE)
1. Introduction
Pre-eclampsia (PE) is a severe placenta-related syndrome that affects 5–8% of all pregnancies,
representing one of the main causes of fetal-maternal morbidity and mortality in developed
countries [1]. PE is characterized by severe maternal hypertension, proteinuria and exacerbated
systemic and placental inflammation [2]. The syndrome becomes evident only after the 20th weeks
of gestation but it likely originates during first trimester of pregnancy when the trophoblast invades
the maternal decidua causing spiral artery remodeling [1]. In PE, trophoblast invasion is impaired,
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leading to aberrant placental perfusion, oxidative stress and consequent inflammation and endothelial
dysfunction [3,4]. This pathologic environment further promotes the release of pro-inflammatory
cytokines and syncithiotrophoblast debris into the maternal circulation, directly activating the
endothelium thus causing systemic inflammation [4,5].
Among many players of the PE inflammatory response, there is increasing interest in a group
of proteins known as Damage Associated Molecular Patterns (DAMPs) that work as an endogenous
danger signal [6,7]. DAMPs have been highlighted as key inflammation activators during PE, preterm
labor and pregnancy-related metabolic dysfunction [7]. The High Mobility Group Box 1 (HMGB1) is
considered the “prototype” of DAMPs. Discovered 40 years ago as non-histone chromatin associated
protein [8], HMGB1 is directly released from activated monocytes and macrophages or passively
discharged by damaged/necrotic cells to induce inflammatory cytokines production [9,10], immune cells
maturation and tissues remodeling [11,12]. The main mediator of HMGB1 inflammatory activity is the
Receptor of Advanced Glycation End products (RAGE) [13]. After HMGB1 binding, RAGE activates
the Nuclear Factor kappa B (NF-kB) pathway which induces the production of pro-inflammatory
cytokines as Interleukin 6 (IL-6) and Tumor Necrosis Factor α (TNF-α) [14]. IL-6 is pivotal for the
acute phase response [15] while TNFα, beside its typical immunomodulatory activities, inhibits first
trimester extravillous trophoblast invasion by triggering apoptosis and decreasing cytotrophoblast
proliferation [16,17]. Importantly, IL-6 [18,19] and TNFα over-expression were reported in the placental
tissue and maternal serum of PE women [16,19,20].
HMGB1 involvement in inflammatory diseases has been widely demonstrated and the administration
of anti-HMGB1 antibodies resulted in decreased organ damage and mortality in several models of
exacerbated inflammation [15–19]. In PE pathogenesis and placental inflammation, the HMGB1/RAGE
role is controversial. In PE placentae, HMGB1 was found increased [20,21] while RAGE expression
was reported either significantly higher [22] or unchanged [20].
Despite intensive investigation on PE pathogenesis, no effective therapy is currently available
except for a timed and often pre-term delivery. This intervention can resolve maternal symptoms but
it could be extremely dangerous for the fetus, causing also severe long-term sequelae. Low Molecular
Weight Heparin (LMWH), a renowned anti-coagulant, has been recently investigated as a therapeutic
approach for preeclampsia and other pregnancy-related complications. The anticoagulant therapy was
first proposed for pregnant women with thrombophilia, characterized by utero-placental thrombosis
and poor obstetric outcomes [23]. The use of anticoagulants during pregnancy was suggested more
than 40 years ago for women which underwent previous placental infarction [24]. The rationale
was that a better placental function might be obtained by reducing the risk of placental thrombosis,
thus improving pregnancy outcomes in high-risk subjects [25]. However, heparin seems to not exert
an anticoagulant effect on the placental tissue since its administration does not improve placental
thrombotic injury rate [26]. Interestingly, heparin improves pregnancy outcomes with a decrease
of placental-mediated complications also in women without thrombophilia [25,27]. In a recent
systematic review and meta-analysis, Rodger and colleagues reported that LMWH reduces the risk
of preeclampsia recurrence, indicating LMWH as a promising therapeutic tool for PE syndrome [28].
However, heparin use for preeclampsia treatment is still controversial and its placental mechanism of
action is unclear. It has been proposed that the beneficial effects of LMWH on PE patients are correlated
to an anti-inflammatory action. Heparin and its derivatives have been demonstrated to be effective
against several inflammatory experimental conditions as mouse models of colitis [29], arthritis [30]
and in patient with airways inflammatory disease [31]. Furthermore, it has been shown that, in an
inflammation-model of mice treated with LPS, modified heparin with low/absent anticoagulatory
capacity strongly inhibited expression of hepcidin, serum iron uptake regulator whose levels rise
during inflammation [32].
Importantly, it has been demonstrated in vitro that heparin reduces HMGB1 affinity for
RAGE [33,34]. HMGB1 possesses heparin-binding ability [35] and it undergoes conformational
change when mixed with LMWH [34]. Moreover, HMGB1-stimulated macrophages and Human
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Umbilical Vein Endothelial Cells (HUVEC) reduce IL-6 and TNF-α release when treated by heparin in
a dose-dependent manner [34].
Our hypothesis is that LMWH inhibition of the placental pro-inflammatory HMGB1/RAGE axis
could contribute to the anti-inflammatory activity observed in heparin-treated pre-eclamptic patients.
In the present study, we evaluated placental HMGB1 and RAGE expression in physiological and
PE pregnancies and we investigated whether LMWH could modify placental HMGB1 and RAGE
expression and/or their binding ability in the human placental tissue.
2. Results
2.1. Study Population
Clinical features of the study population are reported in Table 1. Physiological (n = 19) and PE
(n = 18) patients were comparable in terms of maternal age and parity. As expected, PE group was
characterized by significantly lower gestational age (p < 0.001), birth weight (p < 0.01) and placental
weight at delivery (p < 0.001) relative to control pregnancies.
Table 1. Clinical features of the study population. Values are expressed as median (range) and
percentage. A.G.A, appropriate for gestational age; FGR, fetal growth restriction; n.s. not significant.
Physiological
(n = 19)
Preeclampsia
(n = 18) p Value
Nulliparae (%) 47.36 50 n.s.
Gestational age at delivery (weeks) 39.4 (38–41) 32.8 (28–37) <0.001
Maternal age at delivery (years) 34 (23–39) 34 (20–41) n.s.
Ethnicity (%)
Caucasian 89.47 86.33 n.s.
Prenatal medications (%)
Albumin - 11.11 n.s.
Antibiotics 42.1 16.67 n.s.
Antidepressant - - -
Diuretics - 16.67 n.s.
Eutirox 5.26 - n.s.
Folin 84.21 94.44 n.s.
Heparin 5.26 16.66 n.s.
Iron 15.79 5.55 n.s.
Proton Pump Inhibitors (PPIs) 5.26 11.11 n.s.
Ventolin - - -
Smokers (%) 15.78 16.67 n.s.
Alcohol (%) 10.52 16.67 n.s.
Previous prenatal admission (%) 5.26 16.67 n.s.
Systolic Blood pressure (mm Hg) 120 (90–140) 162.5 (130–180) <0.001
Diastolic Blood pressure (mm Hg) 75 (60–90) 100 (85–117) <0.001
Proteinuria (g/24 h) Absent 1.2 (0.33–8.28) <0.001
A/REDF (%) 0 50 <0.001
Pathological Uterine Doppler (%) 0 66.67 <0.001
Labor (%) 63 17 p = 0.032
Antibiotics in labor (%) 31.58 83.33 p = 0.04
Delivery to processing (range in hours) 0–3 0–3
Caesarean section (%) 37 83 p = 0.011
Anesthesia (%) 63.15 83.33 n.s.
Local 25 -
p = 0.044Spinal 58.33 93.33
Epidural 16.67 -
General - 6.67
Maternal oxygen given at delivery? (%) - 16.67 n.s.
Birth weight (g) 3550 (2920–4020) AGA (n = 5): 2150 (1110–3180)FGR (n = 13): 1250 (610–1880) <0.001
Placental weight (g) 580 (450–845) 310 (184–650) <0.001
Fetal sex (%) p = 0.061
Male 57.9 22.2
Female 42.1 77.8
Magnesium sulfate (%) - 27.78 p = 0.02
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The presence of fetal-placental compromise was evaluated by Doppler velocimetry of umbilical
and uterine arteries. PE patients had abnormal Doppler velocimetries of umbilical or uterine (50% and
66.67% respectively) arteries, while in eight PE patients (44.44%) both values were pathological. In our
study population, LMWH was given during pregnancy to one patient of the control group (5.26%) and
to three patients of the PE group (16.66%).
2.2. HMGB1 and RAGE Expressions in Physiological and Pre-Eclamptic Placentae
HMGB1 has been widely studied for its ability in stimulating pro-inflammatory cytokines by
binding to its receptor RAGE. Since pre-eclampsia is characterized by exacerbated placental inflammation,
we investigated HMGB1 and RAGE expression in PE compared to physiological placentae.
We reported a significant increase of HMGB1 mRNA levels in PE vs. physiological placentae
(p = 0.018, 2.67 fold increase, Figure 1A, left panel). Data were confirmed at the protein level where
we found a 1.76 Fold Increase in PE placentae relative to controls (p = 0.001, Figure 1A, right panel).
Western blot analysis for RAGE did not reveal difference in its protein expression between pathological
and control tissues (Figure 1B).
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Figure 1. HMGB1 and RAGE expression levels in normal (N = 19) versus PE (N = 18) placentae. (A) 
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Figure 1. HMGB1 and RAGE expression levels in normal (N = 19) versus PE (N = 18) placentae.
(A) HMGB1 mRNA (left panel) and protein (right panel) expression levels as assessed by Real
Time PCR and western blot analysis; (B) RAGE protein expression assessed by western blot.
Statistical significance (*) has been considered as p < 0.05.
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Since PE is often associated with Fetal Growth Restriction (FGR) [36,37], we investigated whether
HMBG1 expression in PE placentae could be related to fetal growth. We found no significant differences
in placental HMGB1 expression between PE with Appropriate for Gestational Age (AGA) fetuses
PE-FGR placentae (p > 0.05, Figure S1A). Importantly, PE-AGA and PE-FGR placentae were both
characterized by higher gene (PE-AGA vs. Ctrl, p = 0.296, 3.29 Fold Increase; PE-FGR vs. Ctrl, p = 0.019,
2.41 Fold Increase, Figure S1A) and protein (PE-AGA vs. Ctrl, p = 0.028, 1.72 Fold Increase; PE-FGR vs.
Ctrl, p = 0.02, 1.77 Fold Increase, Figure S1B) HMGB1 expression levels relative to physiological controls.
Next, we compared HMGB1 levels in early-onset versus late-onset PE in order to highlight a
possible relation between HMGB1 expression and gestational age during preeclampsia. We did not
find significant differences in HMGB1 gene and protein expression levels between early- and late-onset
PE (p > 0.05, Figure S2A,B).
Finally, since labour is a pro-inflammatory condition [38], we investigated whether HMGB1
expression was affected by the onset of labour. No significant differences were found in HMGB1
mRNA and protein levels in placentae from patients in labour relative to those that underwent
caesarean section (CS) in both control and PE groups (p > 0.05, Figure S3A,B).
2.3. LMWH Effect on HMGB1 and RAGE Expression in Physiological Human Villous Explants
Low Molecular Weight Heparin, widely known for its anti-coagulant properties, has beneficial
effects on PE patients that look correlated to an unspecified anti-inflammatory activity. Therefore, we
next investigated whether LMWH could modulate placental HMGB1-mediated inflammation in
physiological tissues. Since recent evidences demonstrated that LMWH dose-response is highly
variable [39], we tested LMWH effects at 24 and 48 h using concentrations of 0.5 and 5 units/mL to
span the range of maternal circulating plasma levels found in pregnant women receiving subcutaneous
injections of prophylactic (5000 units/day; equivalent to 0.25 units/mL) or therapeutic (more than
10,000 units/day; equivalent to 2.5 units/mL) doses [40,41]. 5 U of LMWH resulted toxic to our model
as we reported, as a sign of tissue degradation, an abnormally low expression of housekeeping gene
18S (data not shown). Therefore, we considered only data obtained from 0.5 U LMWH-treated explants.
After 24 h, we found significantly increased HMGB1 gene expression in treated compared to control
explants (p = 0.001, 2.32 fold increase, Figure 2A). In contrast, we found a significant decrease of
HMGB1 gene expression in 48 h in LMWH-treated explants relative to controls (p = 0.036, 2.22 fold
decrease, Figure 2A). Data were confirmed at the protein level by western blot analysis. We found
a significant increase in HMGB1 protein levels (p = 0.029, 2.5 fold increase, Figure 2B) at 24 h that
markedly decreased at 48 h in LMWH explants versus controls (p > 0.05, 1.78 fold decrease, Figure 2B).
Finally, we investigated whether LMWH could modulate RAGE expression. Western blot data
showed no significant differences in RAGE protein levels between LMWH-treated and untreated
explants at 24 h, while RAGE protein expression was significantly inhibited at 48 h after LMWH
treatment (p = 0.014, 1.85 Fold decrease) (Figure 3). Our findings suggest the ability of LMWH to
modulate both HMGB1 and RAGE expression in term human placental villous explants.
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Figure 2. HMGB1 expression in LMWH-treated vs. untreated physiological placental villous explants.
(A) HMGB1 mRNA expression levels in placental villous explants treated for 24 h (ctrl n = 8 and 0.5 U
LMWH n = 10) and 48 h (ctrl n = 11 and 0.5 U LMWH n = 10) by 0.5 U of LMWH or plain culture
medium, assessed by Real Time PCR; (B) Representative western blot for HMGB1 protein expression in
LMWH-treated vs. untreated placental villous explants for 24 h (ctrl n = 4 and 0.5 U LMWH n = 4) and
48 h (ctrl n = 10 and 0.5 U LMWH n = 10). Statistical significance (*) has been considered as p < 0.05.
2.4. 0.5 U LMWH Treatment Did Not Affect Physiological Term Placental Villous Explants Viability
To evaluate whether 0.5 U LMWH affects placental explants viability, we performed the Lactate
Dehydrogenase (LDH) assay. This test determines cell membrane integrity by measuring cellular LDH
release/leakage. After 24 h and 48 h of treatment, we observed that the relative LDH amount released
into the media was comparable among basal culture medium treated explants and those treated by 0.5 U
LMWH (p > 0.05, Figure S4). Importantly, LDH levels in all treated explants were significantly lower
compare with the cytotoxicity cut-off value of 41% ranging from 0.13 to 0.56% LDH release (p < 0.05,
Figure S4). Therefore, 0.5 U LMWH treatment does not affect cell viability (p < 0.05, Figure S4).
2.5. LMWH Inhibits HMGB1/RAGE Interaction
HMGB1 pro-inflammatory effect is mediated by its interaction with RAGE. Indeed, we
investigated the ability of HMGB1 to bind its receptor after 24/48 h LMWH treatments. To reach
our goal we performed RAGE immunoprecipitation followed by HMGB1 western blot. We found
a significant decrease in HMGB1 protein levels (p = 0.011, 1.27 fold decrease, Figure 4A) in 24 h
LMWH-treated explants. In contrast, we found no differences of HMGB1 relative to untreated controls
in 48 h-treated villous explants (Figure 4A). To further confirm our findings, we also determined
HMGB1 protein levels in the IP supernatants. Western blot analysis revealed a significant increase
of free HMGB1 in the supernatants at both 24–48 h LMWH-treated explants compared to untreated
controls (p < 0.001 and p = 0.017 respectively, 3.17 and 1.61 fold increases, respectively, Figure 4B).
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Figure 3. RAGE expression in LM H-treated vs. untreated physiological placental villous explants.
Representative western blot for RAGE protein expression level in physiological term placental villous
explants treated for 24 h (ctrl n = 7 and 0.5 U LMWH n = 7) and 48 h (ctrl n = 10 and 0.5 U LMWH n = 10)
by 0.5 U of LMWH.
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explants. HMGB1 operates as transcription factor when it is localized in the nucleus, while it acts
s a pro-inflammatory cyt kine whe released from the cytoplasm to the extracellular environment.
HMGB1 IF staining was mainly localized in mesenchymal (M) and endothelial cells and absent in the
syncytiotrophoblast (TR) layer (Figure 5A–C). Importantly, IF confirmed RNA and protein ata at 24 h
of LMWH treatment. Immunoreactivity for HMGB1 was markedly increased in mesenchymal and
endothelial cells nuclear, peri-nuclear and cyto lasmic areas in LMWH-treated explants (Figure 5B–D)
relative to untr ated controls (Figure 5A–C).
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Figure 5. HMGB1 spatial localization in untreated or 0.5 U LMWH treated physiological villous
explants assessed by immunofluorescent staining. (A–C) HMGB1 spatial localization in untreated
(n = 6) physiological villous explants assessed by immunofluorescent staining; (B–D) HMGB1 spatial
localization in physiological villous explants treated with 0.5 U of LMWH (n = 6); (E) Absence of
positive immunoreactivity for HMGB1 in section stained with control IgG. Cell nuclei are showed in
blue by DAPI signal. TR, trophoblast cells; M, mesenchyme; V, vessel. Original magnifications, 60×.
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Figure 6. IL-6 and TNFα mRNA expression in LMWH-treated explants vs. controls assessed by Real 
Time PCR. (A) IL-6 gene expression in villous explants treated by 0.5 U of LMWH for 24 h (ctrl n = 8 
and 0.5 U LMWH n = 10) and 48 h (ctrl n = 11 and 0.5 U LMWH n = 10). (B) TNFα gene expression 
levels in villous explants treated by 0.5 U of LMWH for 24 h (ctrl n = 8 and 0.5 U LMWH n = 10) and 
48 h (ctrl n = 11 and 0.5 U LMWH n = 10). Statistical significance (*#) has been considered as p < 0.05. 
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of soluble RAGE (sRAGE) in PE [21,42]. Their PE patients were selected by means of systolic/diastolic 
blood pressure >140/90 mmHg and proteinuria >0.3 g/24 h and no stratification of severe cases was 
made. In contrast, Holmlund and colleagues included severe cases (systolic/diastolic blood pressure 
>160/110 and proteinuria >3 g/24 h) but they did not find a correlation with HMGB1 placental 
expression and PE severity [20]. 
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contribute to the pro-inflammatory cytokines production and/or they could be a consequence of the 
placental ischemic damage typical of PE. Recently, it was reported that serum HMGB1 levels are 
increased in pregnant relative to non-pregnant women and that this increase is more dramatic in PE, 
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we demonstrated that placental HMGB1 increase during pre-eclampsia is not related to the presence 
of fetal growth restriction. In accordance to our results, Chen and colleagues reported no significant 
difference in HMGB1 levels between PE-AGA and PE-FGR placentae [44]. Taken together, all these 
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We did not find any association between PE onset (early or late) and HMGB1 expression levels. 
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Figure 6. IL-6 and TNFα mRNA expression in LMWH-treated explants vs. controls assessed by Real
Time PCR. (A) IL-6 gene expression in villous explants treated by 0.5 U of LMWH for 24 h (ctrl n = 8
and 0.5 U LMWH n = 10) and 48 h (ctrl n = 11 and 0.5 U LMWH n = 10). (B) TNFα gene expression
levels in villous explants treated by 0.5 U of LMWH for 24 h (ctrl n = 8 and 0.5 U LMWH n = 10) and
48 h (ctrl n = 11 and 0.5 U LMWH n = 10). Statistical significance (*#) has been considered as p < 0.05.
3. Discussion
In the present study, we reported increased expression of HMGB1, a potent inducer of
pro-inflammatory cytokines, in placentae from pregnancies complicated by pre-eclampsia compared
to physiological controls. We did not find differences in the expression of HMGB1’s receptor RAGE
in PE tissues relative to controls. Next, we evaluated LMWH effect on HMGB1/RAGE expression
and association as well as on HMGB1 target genes IL-6 and TNFα in a physiological placental villous
explants model. After 24 h, LMWH promoted HMGB1, IL-6 and TNFα while it did not influence
RAGE expression. Importantly, HMGB1/RAGE binding was inhibited by LMWH at 24 h, as further
demonstrated by the accumulation of free HMGB1 in treated explants. Finally, HMGB1, RAGE, IL-6
and TNFα were down-regulated at 48 h after 0.5 U LMWH treatment. Our data indicate that LMWH
modulates the HMGB1/RAGE pro-inflammatory axis in the human placenta.
HMGB1 placental expression was first reported in 2007 by Holmlund and colleagues, that
described its localization in both syncithiotrophoblast and chorionic mesenchyme [20]. Herein we
reported a significant over-expression of HMGB1 in PE placentae, characterized by exacerbated
inflammation. In accordance to our results, Wang and colleagues previously reported increased
HMGB1 levels in the placentae, but not in the serum, of pre-eclamptic patients [20,21]. Importantly, they
found no association between gestational age and HMGB1 serum concentration [21], hypothesizing
that the lack of correlation between placental and systemic HMGB1 levels could be due to a source of
circulating HMGB1 different from the placenta and/or to the elevated serum levels of soluble RAGE
(sRAGE) in PE [21,42]. Their PE patients were selected by means of systolic/diastolic blood pressure
>140/90 mmHg and proteinuria >0.3 g/24 h and no stratification of severe cases was made. In contrast,
Holmlund and colleagues included severe cases (systolic/diastolic blood pressure >160/110 and
proteinuria >3 g/24 h) but they did not find a correlation with HMGB1 placental expression and
PE severity [20].
The elevated HMGB1 levels that we described in the pre-eclamptic placental tissue could
contribute to the pro-inflammatory cytokines production and/or they could be a consequence of
the placental ischemic damage typical of PE. Recently, it was reported that serum HMGB1 levels are
increased in pregnant relative to non-pregnant women and that this increase is more dramatic in PE,
without differences between moderate and severe pre-eclampsia [43]. In line with these data, herein
we demonstrated that placental HMGB1 increase during pre-eclampsia is not related to the presence
of fetal growth restriction. In accordance to our results, Chen and colleagues reported no significant
difference in HMGB1 levels between PE-AGA and PE-FGR placentae [44]. Taken together, all these
findings suggest the presence of a common pathogenesis between PE-AGA and PE-FGR pregnancies.
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We did not find any association between PE onset (early or late) and HMGB1 expression levels.
Our data are in agreement with Chen and colleagues that, using semi-quantitative analysis of the
immunohistochemistry and western blotting, showed no significant differences in the levels of HMGB1
in the syncytiotrophoblast from early-onset relative to late-onset PE and control pregnancies [44].
Importantly, in the present study we focused only on the last trimester of pregnancy since it is
correlated to the onset of PE clinical symptoms. Our future investigation will be consider HMGB1
expression throughout gestation.
Elevated HMGB1 was observed in pregnant women with other pro-inflammatory conditions as
obesity [45] and pre-term labor [46]. It is well established that labour is associated to a pro-inflammatory
systemic response [38]. Since HMGB1 is a potent inflammatory cytokine, we investigated placental
HMGB1 expression in labour versus caesarean section deliveries, but no differences were observed in
both control and PE groups. In line with our results, Holmlund and colleagues described no significant
differences in HMGB1, RAGE, TLR2 or TLR4 expression between labour and CS placentae [20].
Thus, different stress stimuli, not only of placental origin, could be responsible for the elevated
HMGB1 levels observed. It was shown that JEG-3 choriocarcinoma cells expressed and released
large amount of HMGB1 under PE-like hypoxic conditions [47], suggesting a possible involvement of
placental HMGB1 in the instauration of the PE exacerbated inflammation [48,49].
Extracellular HMGB1 exerts its cytokine-like activity by binding to RAGE receptor. RAGE increases
with pregnancy onset and it is further augmented in the PE myometrium [22]. Moreover, RAGE protein
expression was found significantly higher in syncithiotrophoblast and endothelial cells of PE placentae
relative to controls [50]. In stark contrast, herein we did not find differences in RAGE expression
between PE and control placentae. In accordance with our findings, other groups found abundant
RAGE expression in trophoblast and decidua of normal term placentae but no differences in PE versus
normal tissues [20]. Variable results could be due to differences in the specimens used. We analyzed
the whole placental tissue instead of isolated trophoblast or endothelial cells.
Several evidences indicate beneficial effects of LMWH for PE treatment. LMWH seems to
improve the maternal-fetal outcomes [27] and to reduce pregnancy-complications recurrence [28].
Moreover, LMWH effects are unrelated to the heparin anti-coagulatory activity [26,27]. It has been
shown in vitro that conditioned media from heparin-treated placental villi exerted a pro-angiogenic
activity on Human Umbilical Vein Endothelial Cells (HUVECs) [40] and that LMWH promotes
trophoblast turnover by stimulating cytotrophoblast proliferation and syncytial fusion [41].
However, Drewlo and colleagues demonstrated that LMWH could stimulate the placental expression
and release of anti-angiogenic soluble Vascular Endothelial Growth Factor (VEGF) receptor-1 (sFLT)
and thus they recommended caution for LMWH use during severe PE [41].
Indeed, LMWH use is controversial and its mechanism of action on the placental tissues is
still unclear. In vitro studies suggested LMWH ability to reduce trophoblast apoptosis through
the modulation of anti-apoptotic B-cell lymphoma (Bcl-2) family molecules [51] and to promote
the invasiveness of extravillous trophoblast by enhancing Matrix metalloprotease-2 (MMP-2),
heparin binding-Epidermal Growth Factor (HB-EGF) and cysteine-rich angiogenic inducer 61 (Cyr61)
activities [52]. Herein, we reported LMWH ability to modulate the pro-inflammatory HMGB1/RAGE
axis in physiological term placental tissues. We found that HMGB1/RAGE interaction was inhibited
by LMWH after 24 h of treatment as demonstrated by immunoprecipitation assay. This effect could
be due to the LMWH-induced HMGB1 conformational change previously demonstrated in vitro [34].
Since RAGE binds heparin too [33], we could not exclude that LMWH could have blocked also the
HMGB1 receptor.
Furthermore, HMGB1/RAGE complex could modulate NFkB activation that, in turn, promotes
RAGE expression [53]. Thus, RAGE reduction reported herein at 48 h of treatment could be directly
due to LMWH-mediated inhibition of HMGB1/RAGE complex. The initiation of a pro-inflammatory
loop by HMGB1 has been suggested in several models of pathological inflammation as multiple
sclerosis [54], necrosis [55] and preterm birth [56]. In PE, LMWH might be able to slow or even stop
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the HMGB1-induced pro-inflammatory loop preventing the exacerbation of inflammation typical of
this syndrome.
Taken together, our data confirm the ability of low molecular weight heparin to block the
HMGB1/RAGE interaction in vitro in placental villous explants. One limitation of the present study
is that we did not experimentally confirm the LMWH-induced HMGB1 conformational change.
Moreover, HMGB1 possesses other receptors like the Toll Like Receptor (TLR) 2 and TLR4 that lead to
NFkB nuclear translocation as well [57,58]. It has been recently demonstrated that 2-O, 3-O-desulfated
heparin, characterized by significant anti-inflammatory but minimal anti-coagulatory properties, is
able to inhibit HMGB1 interaction with TLR2 and TLR4 [59]. Indeed, TLR2 and TLR4 could have
contributed to the heparin-driven modifications reported in the present study. Further investigations
are required.
Since its discovery in the late 1990s, HMGB1 was mainly considered as a nuclear protein
but evidences were accumulating about its extracellular cytokine-like function. Similar to other
cytokines, HMGB1 is pleiotropic with cell-specific activities in the placental tissue [20]. Previous data
showed that HMGB1 induced migration and sprouting in endothelial cell and promoted trophoblast
invasiveness [60,61]. Zhu and colleagues reported HMGB1 cytoplasmatic localization in the PE
placenta while in physiological term pregnancies it was described in the placental nuclei [62].
These data suggest that nuclear-cytoplasmatic translocation may participate in the pathogenetic
process of Preeclampsia. In line with these results, we found a stronger nuclear/perinuclear
HMGB1 signal relative to the cytoplasm. In all LMWH-treated and untreated physiological term
placental explants. Moreover, we showed that HMGB1 signal was mainly localized in the chorionic
mesenchyme and endothelial cells. Our findings are in accordance with Holmlund and colleagues
that found HMGB1 nuclear expression in both chorionic mesenchyme and endothelial cells [20,60].
In contrast, previous studies described a strong HMGB1 positivity in both syncytiotrophoblast and
extravillous trophoblast [20,62].
The activation of HMGB1/RAGE pathway promotes the transcription of IL-6 and TNF-α [34,53].
In our model, the inhibition of IL-6 and TNF-α expression was evident after 48 h of LMWH-treatment.
Taken together, our data confirmed the ability of low molecular weight heparin to block HMGB1/RAGE
interaction and the expression of their target genes in an in vitro model of placental villous explants.
The increase in HMGB1, IL6 and TNFα expression at 24 h in response to LMWH suggest an
initial inflammatory stress being counteracted by heparin as demonstrated by the inhibition of
HMGB1/RAGE binding reported in the present study. It is well established that heparin could directly
modify HMGB1 structure altering its interaction with RAGE, that in turn leads to a decrease of IL-6 and
TNF-α expression [34]. Importantly, HMGB1 transcription itself is stimulated by pro-inflammatory
TNF-α [63] as well as TNF-α could promote HMGB1 release from inflammatory cells [14,64]. Thus, the
inhibition of TNF-α production exerted by LMWH could have indirectly contributed to HMGB1
down-regulation that we reported.
In conclusion, our data depicted a new molecular mechanism through which LMWH exerts its
anti-inflammatory activity on the placental tissue. We underlined the importance of the HMGB1/RAGE
axis in the placental inflammatory response thus opening new directions in the investigation of
PE pathogenesis and management. Indeed, targeting HMGB1 could be effective to control the
ischemia-related inflammatory damage typical of this syndrome, as already demonstrated in other
pathological models [65–67]. Further investigation is required.
4. Materials and Methods
4.1. Ethics Statement and Place of Recruitment
This study was conducted according to the principles expressed in the Declaration of Helsinki.
The study was approved by the Institutional Review Board of O.I.R.M. S. Anna Hospital and “Ordine
Mauriziano di Torino” (n 337; protocol 11552/C.28.1 07/12/2010) (Turin, Italy). All patients were
Molecules 2017, 22, 1997 13 of 19
recruited at O.I.R.M S. Anna Hospital (Turin, Italy) and provided written informed consent for the
collection of samples and subsequent analysis.
4.2. Study Population and Tissues Collection
The study populations included pre-eclamptic singleton pregnancies (n = 18) and physiological
control term pregnancies (n = 19). PE was defined by presence of pregnancy-induced hypertension
(systolic >140 mmHg, diastolic >90 mmHg) and proteinuria (>300 mg/24 h) after the 20th weeks
of gestation in previously normotensive women [1]. Fetal Growth Restriction (FGR) was defined as
birth weight below the fifth centile according to the Italian growth curves normalized for gestational
age and sex [36,37] accompanied by pathological umbilical artery Doppler waveforms (absent or
reverse end diastolic flow—A/REDF) and/or increased resistance to flow in maternal uterine arteries
(early diastolic notch or pulsatility index—PI—more than 0.58). Early-onset PE was defined as
preeclampsia that develops before 34 weeks of gestation, whereas late-onset preeclampsia develops
at or after 34 weeks of gestation [68]. Physiological controls were obtained from normal term
healthy singleton pregnancies that did not show any signs of preeclampsia or other placental disease.
We did not use “age-matched” control pregnancies since no pre-term delivery is physiological.
Patients with cardiovascular diseases, diabetes, metabolic syndrome, infections, kidney disease,
congenital malformations and chromosomal anomalies (number and/or structure) were excluded.
Placental tissue biopsies were randomly collected from the basal plate and snap frozen immediately
after delivery. Calcified, necrotic and visually ischemic areas were excluded from collection. Eight
additional physiological term placentae were collected and processed for placental villous explants
preparation as described below.
4.3. Human Chorionic Villous Explants Cultures and LMWH Treatment
Biopsies from physiological term placentae (n = 8) were processed within 2 h from delivery.
This model allowed us to determine the sequence of molecular events in healthy tissues characterized
by conserved physiological pathways, thus avoiding biases due to previous existing pathological
anomalies. Amniotic membranes were mechanically removed, and placental specimens were washed
in cold phosphate-buffered saline (PBS) solution to eliminate excess of blood. Small portions of
placental chorionic villi were excised and placed in a 24-well culture dishes (35 mg, n = 142).
Explants were cultured in Ham’s F12 media (Gibco by Life Technologies, Monza, Italy) and incubated
at 37 ◦C and 5% CO2 to equilibrate overnight. Explants were then removed from the culture media
and placed in 500 µL of medium with different LMWH (Parnaparin, Alfa Wassermann, Bologna, Italy)
concentrations: 0.5 U and 5 U. Explants in basal culture medium were used as controls. Finally, control
and treated explants were collected after 24 h or 48 h and immediately frozen for RNA and protein
isolation (n = 130) or fixed for histological analyses (n = 12).
4.4. Lactate Dehydrogenase (LDH) Cytotoxicity Assay
Cytotoxicity of 0.5 U LMWH treatment on villous explants was determined by LDH-Cytotoxicity
colorimetric assay (Cat. No. K726-500, Biovision Inc., Milpitas, CA, USA) performed using 24 h
and 48 h explants supernatant according to the manufacturer’s instructions. Explants treated by
Triton X-100 and by basal culture medium for 8 h were used as high (H, 100%) and low controls (0%)
respectively. The positive control (+) was provided by the manufacturer to test whether all reagents
were working properly responding to active LDH enzyme. The absorbance at 450 nm was measured
using a plate reader spectrophotomether. Percent cytotoxicity values were determined based on
the amount of LDH released from 30-min readings, as follows: (test sample − low control)/(high
control − low control) × 100. The cut-off values for the LDH assay was determined by the 2 × SD rule
where the threshold is defined as 2 × SD beyond the mean of the screened samples. Values equal or
exceeding the threshold were considered as sign of cytotoxicity.
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4.5. RNA Isolation and Real Time PCR
Total RNA was extracted from frozen placental biopsies and explants using TRI reagent
(Sigma-Aldrich, Milano, Italy) according to manufacturer instructions and next treated with DNAse
I to remove genomic DNA contamination. Three µg of total RNA were reverse transcribed using a
random hexamers approach (Fermentas Europe, St. Leon-Rot., Germany). Gene expression levels of
HMGB1, IL-6 and TNFα were quantified by Real-time PCR using specific TaqMan primers and probes
following manufacturer’s protocol (Life Technologies). For the relative quantitation, PCR signals were
compared among groups after normalization using ribosomal 18S RNA expression as internal reference
(Life Technologies). 18S mRNA expression was not affected by LMWH treatment. Relative expression
and fold change were calculated according to Livak and Schmittgen [69].
4.6. Western Blot Analysis
Total proteins were isolated from placental biopsies and villous explants using 1X Radio
Immuno-precipitation Assay (RIPA) buffer supplemented with Protease Inhibitors. Thirty µg of
protein were processed by SDS-page electrophoresis on 4–20% polyacrylamide pre-cast gradient gels
(Bio-Rad Laboratories S.r.l., Segrate, Italy). Next, proteins were transferred on polyvinylidene fluoride
(PVDF) membranes and probed at room temperature with primary antibodies using the SnapID
2.0 system (Merck-Millipore, Vimodrone, Italy) following manufacturer instructions. The following
primary antibodies were used: mouse monoclonal anti-human HMGB1 (1:1500 dilution, Sigma-Aldrich,
Milano, Italy) and anti-human RAGE (1:500 dilution, Santa Cruz Biotechnology, D.B.A. Italia S.R.L,
Segrate Italy). Biotinylated secondary antibodies were goat anti-mouse for HMGB1 and RAGE
(1:20.000 dilution and 1:2000 dilution respectively, Santa Cruz Biotechnology, D.B.A. Italia S.R.L,
Segrate Italy). Protein expression levels were normalized to β-actin by blotting with mouse monoclonal
anti-human β-actin antibody (1:1000, Sigma–Aldrich, Milano, Italy). Blots were visualized using
“Luminata Classico” Western HRP substrate (Merck-Millipore, Vimodrone Italy) for HMGB1 according
to manufacturer’s instructions and followed by densitometry.
4.7. HMGB1 Immunofluorescence (IF) Staining
0.5 U LMWH-treated (n = 6) and untreated (n = 6) villous explants were fixed in 4%
paraformaldehyde and embedded in paraffin. Sodium citrate antigen retrieval was performed,
followed by Sudan Black treatment (0.1% Sudan Black in 70% EtOH) to quench endogenous
fluorescence. Sections were pre-incubated in 5% horse serum in PBS (contained 0.04% sodium azide
and 0.008% gelatin) to block nonspecific binding and incubated with primary antibodies overnight
at 4 ◦C. Mouse polyclonal antibodies anti-human HMGB1 (1:1000 dilution; Sigma-Aldrich, Milano,
Italy) was used. Control IgG were used as negative controls. Slides were treated with 0.4% DAPI
(4′,6-diamidino-2-phenylindole) for nuclear detection. IF images were captured using Confocal Nikon
D-Eclipse C1 microscope (Nikon, Chiyoda, Tokyo, Japan).
4.8. Immunoprecipitation (IP) Assay
Five hundred µg of total proteins from LMWH-treated and control villous explants were incubated
with 2 µg of anti-RAGE antibody for two hours at 4 ◦C on a rotor. Next, 20 µL of G-PLUS-Agarose
beads (Santa Cruz Biotechnology, D.B.A. Italia S.R.L., Segrate, Italy) were added to each sample before
incubation overnight at 4 ◦C on a rotor. Samples were then centrifuged at 2500 rpm for 5 min at 4 ◦C
and the supernatants were removed. Pellets were then washed once with 500 µL of PBS and next two
times using 500 µL of RIPA buffer plus protease inhibitors. Immunoprecipitates and supernatants
were finally processed by western blot analysis for HMGB1 as reported above.
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4.9. Statistical Analysis
Clinical data are presented as median, range and frequencies (percentages) while in figures
as mean and standard error (SE). To compare continuous variables, we used the Mann-Whitney
U Test while for categorical variables the comparison between the 2 groups was done with χ2-test.
Statistical test were carried out using the SPSS statistics version 20 software (IBM Inc., Armonk, NY,
USA) and significance was accepted at p < 0.05.
Supplementary Materials: Supplementary Materials are available online. Figure S1: HMGB1 expression levels in
normal versus PE-AGA and PE-FGR placentae; Figure S2: HMGB1 expression levels in early-onset PE versus
late-onset PE placentae; Figure S3: HMGB1 expression levels in control and PE placentas from women in labour
and from women undergoing elective Caesarean sections (CS); Figure S4: 0,5 U LMWH effect on physiological
term placental villous explants viability.
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